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Abstract
Background: Newborns with hypoxic ischemic encephalopathy (HIE) are at risk for coagulopathy due to systemic
oxygen deprivation. Additionally, therapeutic hypothermia (TH) slows enzymatic activity of the coagulation cascade,
leading to constitutive prolongation of routinely assessed coagulation studies. The level of laboratory abnormality
that predicts bleeding is unclear, leading to varying transfusion therapy practices.
Methods: HIE infants treated with TH between 2008–2012 were included in this retrospective study. Initial,
minimum (min) and maximum (max) values of International Normalized Ratio (INR), activated partial thromboplastin
time (aPTT), fibrinogen (Fib) and platelet (PLT) count (measured twice daily during TH) were collected. Bleeding
was defined as clinically significant if associated with 1) decreased hemoglobin (Hb) by 2 g/dL in 24 hours, 2) transfusion
of blood products for hemostasis, or 3) involvement of a critical organ system. Laboratory data between the
bleeding group (BG) and non-bleeding group (NBG) were compared. Variables that differed significantly
between groups were evaluated with Receiver Operating Characteristic Curve (ROC) analyses to determine
cut-points to predict bleeding.
Results: Laboratory and bleeding data were collected from a total of 76 HIE infants with a mean (±SD) birthweight
of 3.34 ± 0.67 kg and gestational age of 38.6 ± 1.9 wks. BG included 41 infants. Bleeding sites were intracranial
(n = 13), gastrointestinal (n = 19), pulmonary (n = 18), hematuria (n = 11) or other (n = 1). There were no differences
between BG and NBG in baseline characteristics (p > 0.05). Both groups demonstrated INR and aPTT values beyond
the acceptable reference ranges utilized for full tem newborns. BG had higher initial and max INR, initial aPTT,
and lower min PLT and min Fib compared to NBG. ROC analyses revealed that platelet count <130 × 109/L, fib
level <1.5 g/L, and INR >2 discriminated BG from NBG.
Conclusions: Laboratory evidence of coagulopathy is universal in HIE babies undergoing TH. Transfusion strategies
to maintain PLT counts >130 × 109/L, fib level >1.5 g/L, and INR <2 may prevent clinical bleeding in this high
risk population.
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Background
Coagulopathy is one of the many consequences of com-
promised oxygen and blood supply to the neonatal liver
and bone marrow after perinatal asphyxia [1-6]. Thera-
peutic hypothermia (TH), the current standard of care
for hypoxic ischemic encephalopathy (HIE) after peri-
natal asphyxia, is known to slow enzymatic activity
involved in the coagulation cascade [7-15]. Although
prior studies evaluating the safety and efficacy of TH
have not demonstrated increased incidence of major
hemorrhage in cooled versus non-cooled infants [16,17],
most studies report high rates of coagulopathy in this pa-
tient population, often requiring transfusion therapy [18].
Transfusion therapy and coagulation monitoring dur-
ing TH is variable between institutions and practitioners.
It is unclear what laboratory abnormalities are predictive
of bleeding in the setting of hypothermia. Additionally,
it is unclear whether transfusion therapy should target
normalization of standard tests of coagulation versus a
more conservative approach of initiating replacement
only after clinical bleeding is observed. Algorithms
to optimize transfusion therapy to prevent clinical bleed-
ing while minimizing exposure to unnecessary blood
products are needed.
The aim of this study was to identify the thresholds of
International Normalized Ratio (INR), activated partial
thromboplastin time (aPTT), fibrinogen (Fib) and plate-
let (PLT) count that are associated with bleeding in HIE
infants undergoing TH. Identified thresholds can guide
transfusion therapy in this population at high risk for
coagulopathy and clinical bleeding.
Methods
Study population
This retrospective study was conducted at an outborn
level 4 neonatal intensive care unit (NICU) in an academic
free-standing children’s hospital. Infants admitted to the
Children’s National Medical Center (CNMC) NICU and
treated with whole-body TH according to established
criteria and methods [16] between 2008–2012 were identi-
fied from a departmental database. Exclusion criteria
included death during TH (due to incomplete data for
evaluation) and concurrent treatment with ECMO (due to
exposure to systemic heparinization). This research was
performed in accordance with The Declaration of Helsinki
and ethical approval was obtained from the CNMC
Institutional Review Board (IRB# 00002771). A waiver
of informed consent was granted for this retrospective
study and all data were collected in compliance with the
Health Information Portability and Accountability Act.
Data collection
Demographic and clinical data were collected from
the medical record. Laboratory data including initial,
minimum (min) and maximum (max) values of INR,
aPTT, Fib level and PLT count (measured twice daily
during TH per protocol) were also collected. Samples ob-
tained from heparinized lines were treated with hepari-
nase to neutralize the heparin effect prior to aPTT
determination. Infants were stratified into two groups
based on the presence or absence of clinically significant
bleeding, which was defined a priori (according to the
Perinatal Haemostasis Subcommittee of the International
Society on Thrombosis and Haemostasis) as any ob-
served bleeding that 1) decreased hemoglobin (Hb) by
2 g/dL in 24 hours; 2) required blood products for
hemostasis; or 3) was in a critical organ system (e.g. pul-
monary, gastrointestinal or intracranial hemorrhage iden-
tified on MRI performed after TH) [19]. Minor bleeding
events such as peri-intubation bleeding from an endo-
tracheal tube, coffee ground gastric residuals and minor
subdural hemorrhages, likely related to birth trauma,
were not included. Information regarding transfusions of
fresh frozen plasma (FFP), cryoprecipitate, PLTs, and red
blood cells were also recorded. Standard NICU guidelines
for transfusion during the study period included main-
taining hematocrit levels greater than 35% for infants re-
quiring respiratory support, transfusing PLTs for counts
less than 100 × 109/L, and FFP or cryoprecipitate for Fib
less than 1.5 g/L and/or overt clinical bleeding. INR/
aPTT-based decisions for transfusion therapy remained
practitioner dependent, in part stimulating the conduct
of this study.
Availability of supporting data
Readily reproducible materials described in this manu-
script, including all relevant raw data, are freely available
to any scientist wishing to use them for non-commercial
purposes, without breaching participant confidentiality,
and may be obtained by contacting the corresponding
author.
Statistical analysis
Descriptive statistics included mean (±95% confidence
intervals) or median (range) for parametric and non-
parametric continuous variables respectively, and fre-
quencies for categorical data. Laboratory data between
the bleeding group (BG) and non-bleeding group (NBG)
were compared using Student’s T test, Mann–Whitney
U and Chi-Square Tests for independent samples where
appropriate. Variables that reached statistical significance
(P value <0.05) were further evaluated with Receiver
Operating Curve (ROC) analyses in which an area under
the curve (AUC) of 1 denotes 100% agreement between
predicted and actual outcomes, versus an AUC of 0.5
that demonstrates no discrimination between groups.
Cutpoints with optimal specificity and sensitivity were
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selected from the ROC to identify values that predict
clinical bleeding.
Results
A total of 97 infants treated with TH during the study
period were evaluated. Sixteen (16.5%) infants died and
5 (5%) required ECMO during TH and were excluded
from analysis. Complete bleeding and laboratory data
were collected from 76 infants. The BG was comprised
of 41 infants that had bleeding observed from one or
more sites including intracranial (n = 13), gastrointestinal
(n = 19), pulmonary (n = 18), hematuria (n = 11) or pro-
fuse umbilical stump bleeding (n = 1). Bleeding events
were significant enough to require intervention by the
clinical team; ie ventilator settings were escalated in
setting of pulmonary hemorrhage, H2 blockers or
proton-pump inhibitors were started for gastrointestinal
bleeding, and/or coagulation products were given. How-
ever, there were no major life-threatening bleeding
events requiring surgical or neurosurgical interventions.
There were no differences in the baseline or clinical
characteristics between the BG and NBG, except that
more infants with severe encephalopathy were in the BG
(Table 1). Not surprisingly, more infants in the BG
group received blood product transfusions and had a
greater number of transfusions compared to the NBG
group (p < 0.05) (Table 2).
BG had higher initial and max INR, and initial aPTT
than the NBG. Moreover, min PLT count and min Fib
level were lower in the BG versus NBG (Figure 1). Other
parameters did not differ between groups (p > 0.05).
ROC curves are shown in Figure 2. Cutpoints selected
from the ROC curves to predict bleeding include min
Fib level of 1.54 g/L (71% sensitivity, 68.6% specificity,
AUC = 0.695, p = 0.004); min PLT count of 130.5 × 109/L
(71% sensitivity, 62.9% specificity, AUC= 0.695, p = 0.004);
and max INR of 1.98 (73.2% sensitivity, 54.3% specificity,
AUC = 0.666, p = 0.013). The ROC curve for initial aPTT
was not significant.
Discussion
While the safety and efficacy of TH in reducing neuro-
developmental sequelae after asphyxia is well established
[16-18,20,21], establishing evidence based guidelines for
managing coagulopathy during TH can optimize medical
care and contribute to better outcomes. While some
prior studies have reported platelet counts and aPTT/PT
results during hypothermia [7,22], this is the first study
to systematically evaluate the relationship between
laboratory and clinical evidence of coagulopathy in new-
borns undergoing TH. Although major hemorrhages
were not observed, which is consistent with prior ran-
domized trials [22] and recent meta-analyses [18], cli-
nically significant bleeding and associated exposure to
transfusion therapy were highly prevalent in these
critically-ill newborns. The cutpoints provided in this
study provide less arbitrary thresholds for transfusion
therapy in response to commonly followed tests of
coagulation, addressing an important and frequently
encountered comorbidity in newborns with HIE.
Coagulation disturbances after birth asphyxia have
multifactorial origin. Alterations in blood and oxygen
supply to the liver and bone marrow can negatively
impact the synthesis of clotting factors and PLTs re-
spectively [1,3-5]. Disseminated intravascular coagula-
tion (DIC) has also been frequently described following
asphyxia in the newborn [2,6]. Additionally, hypothermia
has the potential to impair hemostasis by slowing
enzymatic function of the coagulation cascade, impairing
thrombin generation, and further triggering DIC
[8,10-14]. Hypothermia also causes PLT dysfunction by
decreasing the levels of thromboxane A2 and platelet
surface expression of the glycoprotein Ib-IX complex
[9,23]. Bleeding risk, therefore, remains an important
problem for infants with HIE undergoing TH. Assess-
ment of bleeding risk is routinely performed by serial
monitoring of aPTT, PT/INR, Fib levels and PLT counts.
Interpretation of these tests is limited by inadequate data
associating these laboratory values with bleeding in the
neonatal population. Additionally, aPTT and PT/INR
and Fib levels are routinely performed at 37°C in the
Table 1 Clinical and demographic characteristics of study
population
Bleeding Non-bleeding P-value
(n = 41) (n = 35)
Birth weight* (grams) 3.376 ± 0.66 3.308 ± 0.69 0.66
Gestational age* (weeks) 38.63 ± 2.11 38.57 ± 1.54 0.884
Gender (n, % male) 25 (61) 22 (62.9) 0.866
Presenting pH 6.95 (6.6–7.34) 6.985 (6.44–7.35) 0.472
5 min Apgar 2 (1–7) 3 (1–7) 0.73
Encephalopathy Grade 0.048
Moderate (n, %) 34 (83) 34 (97)
Severe (n, %) 7 (17) 1 (3)
EEG seizure (n, %) 13 (31.7%) 7 (20%) 0.248
Data presented as median (range) except where indicated.
*Mean ± standard of deviation.
Table 2 Transfusion information
Transfusion type Bleeding n(%) Non-bleeding n(%)
Packed red blood cells 15 (36.6) 5 (14.2)
Fresh frozen plasma 22 (53.7) 11 (31.4)
Cryoprecipitate 13 (31.7) 3 (8.5)
Platelets 17 (41.5) 6 (17.1)
Data presented as n(%) of patients in each group who received transfusion
with product listed.
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laboratory, which may not accurately reflect the in-vivo
condition of a patient undergoing TH. aPTT and PT are
likely to be more prolonged at 33.5°C, thus bleeding risk
may be underestimated if routine norms are considered
in samples that are warmed prior to determination. The
unclear relationship between laboratory abnormalities
and bleeding risk explains why there is no uniformly ac-
cepted protocol for management of coagulopathy in HIE
amongst practitioners and institutions. As a significant
proportion of the NBG received transfusion therapy, it is
presumed that this was done in response to laboratory
derangements alone based on the discretion of pro-
viders. Whether this practice protected these patients
from bleeding risk or whether this represents unneces-
sary exposure to blood products cannot be answered by
the current study.
That the incidence of bleeding reported in this study
(54%) exceeds the rates from published trials is likely at-
tributable to our conservative definition of bleeding [19],
which was selected to encompass bleeding events felt to
be of clinical significance and not confined to only major
or life-threatening events. These events either required
active intervention and/or had risk for independent se-
quelae, as in the case of intracranial hemorrhage. Vari-
able rates of intracranial hemorrhage (8–39%) have been
reported from the randomized cooling trials [24,25] and
it is possible that risk for hemorrhage can be impacted
by variable approaches to correcting coagulopathy. Intra-
cranial hemorrhage, which may or may not be associated
with clinical symptoms, is important to recognize and
serves as a strong counter-argument to transfusion ap-
proaches that only treat overt bleeding. Thus, thresholds
for acceptable laboratory derangements are needed to
direct transfusion therapy in order to ideally prevent
bleeding before it occurs.
While significant associations were found between
these routinely used tests of coagulation and clinical
bleeding, it should be noted that none of the tests ex-
hibited optimal sensitivity and specificity in isolation to
predict bleeding. Thus, a battery of tests must be
followed in combination to provide an overall assess-
ment of coagulation status. Investigation into other
methods to assess coagulation status in this population
is warranted. Thromboelastography, a functional assay
of global hemostatic status that can be performed under
temperature regulated conditions, shows promise [26]
and may improve the approach to assessment and treat-
ment of bleeding risk in this population.
This study has limitations. While the definition of sig-
nificant bleeding used in this study has been proposed
and supported by other investigators, qualifying events
by an associated 2 g/dL drop in Hb may be questioned
Figure 1 Each panel demonstrates a bar graph representing the mean ± SD for initial and max/min value of INR, aPTT, platelet
count and fibrinogen level as labeled. The bleeding group is represented by dark bars and nonbleeding group is represented by light bars.
The * indicates a p value of significance by Independent Samples T-test.
Figure 2 This figure shows the receiver operator curves used to determine cutpoints for the minimum platelet count, minimum
fibrinogen level and maximum INR that predict clinical bleeding. AUC = Area under the receiver operator curve.
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as iatrogenic anemia from frequent laboratory moni-
toring in the NICU is common. However, no bleeding
events were classified as significant in this study based
on the association with acute anemia alone (i.e. all
required acute intervention and/or were identified in a
critical organ system such as intracranial hemorrhage).
Thus, we feel that only significant bleeding events were
included in these analyses. We were unable to address
the temporal relation of laboratory assessments, transfu-
sions and bleeding events in this study. In particular,
diagnosis of intracranial hemorrhage was routinely made
from MRI performed after rewarming. Thus we used the
approach of evaluating bleeding at any point during cool-
ing/rewarming and its association with laboratory values
measured over the course of TH. Due to this approach,
we excluded infants who died during hypothermia as
they would, by definition, have an incomplete and non-
comparable observation period. As these infants were
likely to have coagulopathy with more severe multi-
system disease, their inclusion could have potentially
skewed the data and therefore we proceeded with a more
conservative approach to evaluate only complete labora-
tory and bleeding data from survivors. Our transfusion
practice during the study period did not call for active
transfusion therapy with increased laboratory surveillance
when needed to maintain the goals proposed in this study.
We have since adjusted our practice based on these data
and plan to evaluate whether management of coagulo-
pathy with these proposed transfusion goals reduces
clinical bleeding in babies with HIE undergoing TH.
Conclusions
Clinically significant bleeding is highly prevalent in
neonates with HIE undergoing TH. PLT counts <130 ×
109/L, Fib level <1.5 g/L and an INR of >2 were associ-
ated with increased risk for clinical bleeding in this
population. Further study is needed to determine
whether transfusion therapy according to these thresh-
olds will reduce the incidence of clinical bleeding in ba-
bies with HIE being treated with TH.
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